Skip to main content
. 2020 May 11;10(5):54. doi: 10.1038/s41408-020-0320-7

Fig. 2. Heatmap of the drug sensitivities by unsupervised hierarchical clustering for the 25 HMCLs.

Fig. 2

The top section (resistant) includes the drugs that are mostly inactive in HMCLs. These include decitabine, tofacitinib, vismodegib, vemurafenib, idasanutlin, nelarabine, lenvatinib, fludarabine, and ruxolitinib. The bottom section (sensitive) includes broadly cytotoxic and very potent drugs in HMCLs, including proteasome inhibitors, dinaciclib, venetoclax, HDAC inhibitors, selinexor, ALK inhibitors, and some RTK inhibitors. The center area (differential) includes rapalogues, bromodomain inhibitors, MAPK inhibitors, some inhibitors of RTKs including FLT3, and PIKfyve inhibitors.